跳到正文
原文
NEJM· @NEJM · X·· 25 天前精选AI 评分75
AI 导读

NEJM发布III期RAINIER AIS-D08试验结果,在IgA肾病患者中,BAFF与APRIL双抑制剂povetacicept较安慰剂显著降低蛋白尿。完整结果已在#KidneyWk公布,链接为https://nej.md/3VWcGh6。

推荐理由

原文给出III期RAINIER试验中povetacicept较安慰剂显著降低IgA肾病患者蛋白尿的结果,可供对照同类在研疗法。

正文

Presented at #KidneyWk:

Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo. Full phase 3 RAINIER AIS-D08 trial results: https://nej.md/3VWcGh6

@ASNKidney

来源:NEJM · x.com